Log In
Print
BCIQ
Print
Print this Print this
 

KB004

  Manage Alerts
Collapse Summary General Information
Company KaloBios Pharmaceuticals Inc.
DescriptionHumanized mAb targeting EPH receptor A3 (EPHA3) receptor tyrosine kinase developed using Humaneered technology
Molecular Target EPH receptor A3 (EPHA3)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationHematologic malignancies
Indication DetailsTreat acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS); Treat EPHA3-expressing hematologic malignancies; Treat hematologic malignancies
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today